Ritholtz Wealth Management raised its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 29.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 74,799 shares of the company's stock after purchasing an additional 16,891 shares during the period. Ritholtz Wealth Management's holdings in Johnson & Johnson were worth $12,405,000 at the end of the most recent quarter.
Several other large investors have also recently bought and sold shares of the stock. Tallon Kerry Patrick acquired a new stake in Johnson & Johnson during the fourth quarter worth approximately $290,000. Capital & Planning LLC raised its stake in Johnson & Johnson by 13.6% in the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock valued at $221,000 after purchasing an additional 183 shares in the last quarter. Brighton Jones LLC lifted its position in Johnson & Johnson by 13.9% during the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares during the period. Union Bancaire Privee UBP SA acquired a new stake in Johnson & Johnson during the fourth quarter worth about $85,886,000. Finally, Viewpoint Capital Management LLC raised its position in shares of Johnson & Johnson by 5.1% in the 4th quarter. Viewpoint Capital Management LLC now owns 14,051 shares of the company's stock valued at $2,032,000 after buying an additional 681 shares in the last quarter. 69.55% of the stock is owned by institutional investors.
Johnson & Johnson Trading Down 1.2%
Johnson & Johnson stock traded down $1.86 during trading hours on Monday, reaching $155.24. 7,022,773 shares of the company's stock were exchanged, compared to its average volume of 9,132,877. The firm has a market capitalization of $373.52 billion, a PE ratio of 23.34, a PEG ratio of 2.56 and a beta of 0.42. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm's 50 day simple moving average is $153.84 and its 200 day simple moving average is $153.70. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. Research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.35%. Johnson & Johnson's payout ratio is presently 57.84%.
Wall Street Analyst Weigh In
Several research analysts have commented on JNJ shares. Barclays lowered their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 22nd. Bank of America reduced their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research note on Thursday, April 10th. Finally, Raymond James lowered their price objective on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Eleven research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.
Read Our Latest Analysis on Johnson & Johnson
About Johnson & Johnson
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Recommended Stories
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
